Literature DB >> 24089298

[Dupuytren's disease - patient satisfaction and functional results one year after partial fasciectomy and injection of collagenase].

F H Vollbach1, L Walle, H Fansa.   

Abstract

INTRODUCTION: The gold standard in the treatment of Dupuytren's disease is the partial fasciectomy (PF). Injection of a collagenase directly into the Dupuytren cord is an alternative method. In contrast to needle fasciotomy, destruction of the cord is achieved enzymatically and not mechanically. 24 h after injection, the treated finger can be extended passively to disrupt the Dupuytren cord. PATIENTS AND METHODS: Functional outcome and patient satisfaction were prospectively analysed in 2 comparable groups of patients with the same stage of disease. Follow-up was one year. Patients in the first group underwent partial fasciectomy (PF) (n=13), whereas patients in the second group were treated by an injection of collagenase (CG) in the diseased tissue (n=14). Besides clinical examination, outcome was evaluated by validated questionnaires (DASH/MHQ) and a customised questionnaire.
RESULTS: Extension after PF (mean residual contracture 7.5°) was better than after collagenase injection (mean residual contracture 13.2°). Side-effects like numbness, impaired blood circulation and pain were less after injection of collagenase than after PF and of shorter duration. Recovery of grip strength was faster in the CG than after PF and collagenase injection was regarded as less discomforting. The results of the questionnaires showed a reduction of hand function 1 month after surgery, whereas better results were observed 1 month after collagenase injection. Recovery in the CG was significantly faster than after PF. DISCUSSION: Collagenase injection, as a less invasive technique, has less and milder side-effects than surgery and demonstrated a better total reduction of Dupuytren's contracture initially, although the residual contractures were higher in the CG after follow-up of 1 year. Patient satisfaction was higher after collagenase injection due to subjectively perceived less negative impact and a comparable functional outcome. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24089298     DOI: 10.1055/s-0033-1351329

Source DB:  PubMed          Journal:  Handchir Mikrochir Plast Chir        ISSN: 0722-1819            Impact factor:   1.018


  3 in total

1.  [Treatment of Dupuytren's disease with collagenase Clostridium histolyticum].

Authors:  M Keller; R Arora; G Schmiedle; T Kastenberger
Journal:  Orthopade       Date:  2017-04       Impact factor: 1.087

2.  [Percutaneous needle aponeurotomy for Dupuytren's disease].

Authors:  C K Spies; L P Müller; E Skouras; D Bassemir; P Hahn; F Unglaub
Journal:  Oper Orthop Traumatol       Date:  2015-08-25       Impact factor: 1.154

Review 3.  Surgery for Dupuytren's contracture of the fingers.

Authors:  Jeremy N Rodrigues; Giles W Becker; Cathy Ball; Weiya Zhang; Henk Giele; Jonathan Hobby; Anna L Pratt; Tim Davis
Journal:  Cochrane Database Syst Rev       Date:  2015-12-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.